Literature DB >> 27645473

The incidence and risk factors for central lymph node metastasis in cN0 papillary thyroid microcarcinoma: a meta-analysis.

Liang-Sen Liu1, Jia Liang2, Jun-Hong Li1, Xue Liu1, Li Jiang3, Jian-Xiong Long4, Yue-Ming Jiang4, Zhi-Xiao Wei5.   

Abstract

Although there have been many studies identifying clinical and pathologic factors that may predict central lymph node metastases (CLNM) in papillary thyroid microcarcinoma (PTMC) patients without clinically cervical lymph node metastasis (cN0), the results were inconsistent. And whether prophylactic central lymph node dissection (pCLND) should be performed in cN0 PTMC remains controversial. The EMBASE, PubMed, MEDLINE and the Cochrane Library were searched until Oct 2015 to identify relevant studies. Primary outcomes were clinical and pathologic factors for CLNM. Secondary outcomes included CLNM rate, surgical complications of hypocalcaemia and recurrent laryngeal nerve(RLN) injury and neck recurrences. Statistical analysis was performed using Stata 12.0. Fourteen eligible studies enrolling 4573 patients were included in this meta-analysis. The overall incidence of CLNM was 33 % (95 % CI 29-37). An elevated risk of CLNM was significantly associated with male gender (OR 2.33, 95 % CI 1.71-3.17), age <45 years (OR 1.27, 95 % CI 1.08-1.48), tumor size >5 mm (OR 2.16, 95 % CI 1.87-2.50), multifocality (OR 1.73, 95 % CI 1.45-2.05), extrathyroidal extension (OR 1.99, 95 % CI 1.66-2.37) and lymphovascular invasion (OR 3.87, 95 % CI 1.64-9.10), but not with thyroid bilaterality (OR 1.41, 95 % CI 0.89-2.22) and chronic lymphocytic thyroiditis (OR 0.98, 95 % CI 0.66-1.47). The pooled frequency of permanent hypocalcaemia, permanent RLN injury and neck recurrences was 1.1, 0.5 and 2.8 %, respectively. cN0 PTMC patients have a considerable CLNM rate and have a low pooled incident of surgical complications and neck recurrences with pCLND. Six unfavorable clinical and pathologic factors, which were significantly associated with CLNM, were identified. These findings may help guide the application of pCLND or subsequent treatment in cN0 PTMC.

Entities:  

Keywords:  Central lymph node metastasis; Meta-analysis; Papillary thyroid microcarcinoma; Risk factors

Mesh:

Year:  2016        PMID: 27645473     DOI: 10.1007/s00405-016-4302-0

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  52 in total

1.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  J Clin Epidemiol       Date:  2009-07-23       Impact factor: 6.437

2.  The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis: a meta-analysis.

Authors:  Ju-Han Lee; Younghye Kim; Jung-Woo Choi; Young-Sik Kim
Journal:  Eur J Endocrinol       Date:  2013-02-15       Impact factor: 6.664

3.  Predicting the factors of lateral lymph node metastasis in papillary microcarcinoma of the thyroid in eastern China.

Authors:  Rui-chao Zeng; Quan Li; Kuai-lu Lin; Wei Zhang; Er-li Gao; Guan-li Huang; Xiao-hua Zhang; Min-hua Zheng
Journal:  Clin Transl Oncol       Date:  2012-08-08       Impact factor: 3.405

4.  Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation.

Authors:  Yasuhiro Ito; Akira Miyauchi; Minoru Kihara; Takuya Higashiyama; Kaoru Kobayashi; Akihiro Miya
Journal:  Thyroid       Date:  2013-11-14       Impact factor: 6.568

5.  Multifocality and total tumor diameter predict central neck lymph node metastases in papillary thyroid microcarcinoma.

Authors:  Qunzi Zhao; Jie Ming; Chunping Liu; Lan Shi; Xia Xu; Xiu Nie; Tao Huang
Journal:  Ann Surg Oncol       Date:  2012-09-13       Impact factor: 5.344

6.  Preoperative prediction of central lymph node metastasis in thyroid papillary microcarcinoma using clinicopathologic and sonographic features.

Authors:  Kyung-Eun Kim; Eun-Kyung Kim; Jung Hyun Yoon; Kyung Hwa Han; Hee Jung Moon; Jin Young Kwak
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

7.  Using foci number to predict central lymph node metastases of papillary thyroid microcarcinomas with multifocality.

Authors:  Yawen Guo; Zeming Liu; Pan Yu; Chunping Liu; Jie Ming; Ning Zhang; Maimaiti Yusufu; Chen Chen; Tao Huang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 8.  A Meta-analysis of Central Lymph Node Metastasis for Predicting Lateral Involvement in Papillary Thyroid Carcinoma.

Authors:  Xiabin Lan; Wei Sun; Hao Zhang; Wenwu Dong; Zhihong Wang; Ting Zhang
Journal:  Otolaryngol Head Neck Surg       Date:  2015-08-25       Impact factor: 3.497

9.  Is Hashimoto's thyroiditis a prognostic factor for thyroid papillary microcarcinoma?

Authors:  H Y Bircan; B Koc; C Akarsu; E Demiralay; A Demirag; M Adas; H Alis; O Kemik
Journal:  Eur Rev Med Pharmacol Sci       Date:  2014-07       Impact factor: 3.507

10.  Clinical Characteristics Related to Central Lymph Node Metastasis in cN0 Papillary Thyroid Carcinoma: A Retrospective Study of 916 Patients.

Authors:  Lie-Hao Jiang; Chao Chen; Zhuo Tan; Xiao-Xiao Lu; Si-Si Hu; Qing-Liang Wang; Xiu-Xiu Hou; Jun Cao; Ming-Hua Ge
Journal:  Int J Endocrinol       Date:  2014-08-21       Impact factor: 3.257

View more
  20 in total

1.  Central Lymph Node Metastasis in Papillary Thyroid Carcinoma.

Authors:  Ashok R Shaha
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

2.  Predicting factors of central lymph node metastases in patients with unilateral multifocal papillary thyroid microcarcinoma.

Authors:  Xin Wu; Binglu Li; Chaoji Zheng; Xiaodong He
Journal:  Gland Surg       Date:  2020-06

3.  The relationship between central lymph node metastasis and the distance from tumor to thyroid capsule in papillary thyroid microcarcinoma without capsule invasion.

Authors:  Mengting Zhu; Weihui Zheng; Yangfeng Xiang; Jialei Gu; Kejing Wang; Jinbiao Shang
Journal:  Gland Surg       Date:  2020-06

4.  Analysis of Risk Factors for Lymph Node Metastases in Elderly Patients with Papillary Thyroid Micro-Carcinoma.

Authors:  Gui-Ming Fu; Zhao-Hui Wang; Yi-Bo Chen; Chun-Hua Li; Yue-Jia Zhang; Xiao-Jing Li; Quan-Xin Wan
Journal:  Cancer Manag Res       Date:  2020-08-11       Impact factor: 3.989

Review 5.  The increasing prevalence of chronic lymphocytic thyroiditis in papillary microcarcinoma.

Authors:  Roberto Vita; Antonio Ieni; Giovanni Tuccari; Salvatore Benvenga
Journal:  Rev Endocr Metab Disord       Date:  2018-12       Impact factor: 6.514

6.  Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases.

Authors:  Jingtai Zhi; Jingzhu Zhao; Ming Gao; Yi Pan; Jianghua Wu; Yigong Li; Dapeng Li; Yang Yu; Xiangqian Zheng
Journal:  Int J Clin Oncol       Date:  2017-07-25       Impact factor: 3.402

7.  Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Jingxin Mao; Qinghai Zhang; Haiyan Zhang; Ke Zheng; Rui Wang; Guoze Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-15       Impact factor: 5.555

8.  Clinical Analysis of Risk Factors for Cervical Lymph Node Metastasis in Papillary Thyroid Microcarcinoma: A Retrospective Study of 3686 Patients.

Authors:  Jianlu Song; Ting Yan; Wangwang Qiu; Youben Fan; Zhili Yang
Journal:  Cancer Manag Res       Date:  2020-04-09       Impact factor: 3.989

9.  Randomized trial of prophylactic ipsilateral central lymph node dissection in patients with clinically node negative papillary thyroid microcarcinoma.

Authors:  Bo Young Kim; Nayeon Choi; Sun Wook Kim; Han-Sin Jeong; Man Ki Chung; Young- Ik Son
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-10-29       Impact factor: 3.236

10.  Cell adhesion-related gene somatic mutations are enriched in aggressive papillary thyroid microcarcinomas.

Authors:  Jianlu Song; Shouxin Wu; Xiaotian Xia; Yu Wang; Youben Fan; Zhili Yang
Journal:  J Transl Med       Date:  2018-10-01       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.